Overview

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

Status:
RECRUITING
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
ITB-Med LLC
Treatments:
siplizumab